Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > January 2014

« Previous month Next month »

GSK: Halt in chicken pox vaccine manufacture to continue into Q2

31-Jan-2014 - Shipments of chicken pox vaccines from a troubled Belgian facility should recommence in early Q2 2014, says GSK, though the root cause of the manufacturing issues are still unknown.

Clarus says oral testosterone bulks muscles, not liver

30-Jan-2014 - Clarus Therapeutics has submitted to the FDA a testosterone replacement it claims overcomes the toxicity problems that have plagued other oral drugs like methyltestosterone.

CordenPharma certified to handle HPAPIs under SafeBridge safety programme

30-Jan-2014 - CordenPharma has received certification of Potent Compound Safety at a US plant and joins a growing list of drugmakers looking to assure HPAPI safety, according to SafeBridge Consultants.

Demand for HPAPIs drives Patheon to invest $1m in UK facility

30-Jan-2014 - Increasing demand for HPAPIs has driven Patheon to invest in its Milton Park, UK manufacturing facility, the company says.

Pfizer, Lilly and other giants team up to fight counterfeits

30-Jan-2014 - Big pharma rivals are joining forces to pursue a new generation of sophisticated counterfeiters, according to Pfizer and Eli Lilly.

NW Bio prepares for large-scale manufacturing expansion

29-Jan-2014 - Northwest Biotherapeutics has agreed with CMO Cognate Bioservices to begin a large-scale expansion of the manufacturing, storage, handling and distribution of its personalized immune therapies for solid tumor cancers.

Daiichi says new API import ban will affect Ranbaxy's US ops

27-Jan-2014 - Daiichi-Sankyo says ensuring API supply could be a problem at Ranbaxy’s US finished product sites after imports are banned from yet another of its Indian facilities.

Actavis to sell Foshan JV stake days after calling China 'too risky'

27-Jan-2014 - Actavis has announced plans to sell its stake in its Chinese subsidiary just days after telling investors the country is 'too risky' for new investments.

Vive l’excipact: French Seppic excipients site gets certified

27-Jan-2014 - A French subsidiary of specialty ingredients firm Seppic has become the latest supplier certified under the Excipact quality scheme for drug excipients

Croatian Immunology Institute files for bankruptcy, questions remain

27-Jan-2014 - The future of the organisation that makes many of Croatia’s drugs and immunotherapies is in doubt, with reports suggesting the Government is trying to sell off parts of the state...

Par Pharmaceutical steps into sterile injectables with $490m JHP deal

27-Jan-2014 - Par Pharmaceutical Companies has agreed to buy JHP Group Holdings for $490M (€358M) to add sterile injectables to its offering. 

Hospira intent on growing Indian ops as EU market beckons

23-Jan-2014 - Increased in-house API production and manufacturing in India will lower the costs of Hospira’s injectables, the firm says, as it looks past current remediation efforts.

Confusion over lethal injection drug shortage status

23-Jan-2014 - The contentious drug Midazolam is no longer in short supply, the FDA has told

News in brief

Rexam opens extension at French nasal pump plant

23-Jan-2014 - Rexam has completed its extension of a French plant that manufactures the nasal spray pump product, Advancia.

Hopkinton phasedown hits Lonza's 2013 sales

23-Jan-2014 - Higher earnings and improved margins did not impress investors in Lonza, which saw its share price tumble today after revealing that sales to the drug sector fell in 2013.

Exclusive interview

Lilly backs track-and-trace and commits $102m to fight counterfeits

22-Jan-2014 - Eli Lilly is spending €75m ($102m) to meet latest global anti-counterfeiting regulations, its security experts said in an exclusive interview with

500 jobs to go as Novartis plans to shutter NY Diovan facility

22-Jan-2014 - Novartis says it intends to shutter a New York manufacturing site due to reduced demand following the loss of exclusivity on its one-time topseller Diovan.

Teva outbids Endo to secure $144m NuPathe takeover

22-Jan-2014 - Teva Pharmaceutical Industries has agreed to acquire NuPathe for $144m (€106m) and gain access to the company’s transdermal patch.


EU reliance on API imports is 'alarming' says EFCG

21-Jan-2014 - European dependence on drugs and APIs made outside the EU is still ‘alarming’ despite recently introduced anti-falsified meds laws according to the European Fine Chemicals Group (EFCG).

Companies look to ramp up investments in US IV solutions as shortages persist

21-Jan-2014 - Efforts to address the current shortage of IV fluids in the US are a placing a strain on manufacturing capabilities according to Baxter, which is investing to try and increase...

Aurobindo says it can turn Actavis' units around

20-Jan-2014 - Aurobindo says it can make the loss making European generics operations it is buying from Actavis profitable by combining them with its production network in India.

AMRI targeting higher tech manufacturing and generics as Burlington booms

20-Jan-2014 - AMRI says it intends to expand its fill/finish capability and progress its business into higher value technology following the recent all clear at its once troubled Burlington facility.

People on the Move

People on the Move: the week's changes at GSK, Mylan and Merck

20-Jan-2014 - GSK Nigeria has a surprise MD resignation, Mylan tells us about its expansion in Latin America, and we cover the rest of the week's pharma hires.

US FDA poised to up China inspections after favourable FY14 budget

20-Jan-2014 - The US FDA is positioned to increase drug plant inspections in China after US President Barack Obama signed a $1.1tr (€881bn) budget for fiscal 2014 into law on Saturday.

Complex generics will boost speciality biz, Teva says

16-Jan-2014 - Complex generics will represent over 50% of Teva’s generic market by 2017, the firm says, but investments in delivery technology will have positive implications across the full business.

« Previous month Next month »

Key Industry Events


Access all events listing

Our events, Shows & Conferences...